GlassScriptPhysician profile
Jaskiran K Cheema
NPI 1275795932
$1,037.89
in general payments reported to CMS, 2019-2025
13 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $20.86 · 2021: $51.16 · 2022: $12.99 · 2023: $168 · 2024: $224 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $216.77 | 2021-2025 | Cardiomems |
| Edwards Lifesciences Corporation | $177.42 | 2024-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $119.45 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $116.78 | 2025 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $79.60 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $66.40 | 2021-2024 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.30 | 2024 | Lifevest |
| Pfizer INC. | $42.14 | 2019-2021 | |
| Cleerly, INC. | $41.69 | 2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $39.77 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $34.83 | 2019-2020 | |
| Heartflow, INC. | $19.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaskiran Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.